Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, February 09, 2017 9:54:16 AM
Feb. 9, 2017 9:51 AM ET|About: Kitov Pharmaceuticals ... (KTOV)|By: Douglas W. House, SA News Editor
Kitov Pharmaceuticals (KTOV) reports that the previously announced investigation by the Israeli Securities Authority (ISA) is focused on matters surrounding the Data Monitoring Committee (DMC) appointed to monitor the data in the company's Phase 3 clinical trial of lead product candidate KIT-302. It says the DMC was established to analyze the preliminary results and determine the number of additional patients, if any, needed to show statistical validity and meet the primary endpoint of the study.
It adds that the data were analyzed by a European specialist services provider named Statistica Medica Ltd. Its analysis showed that the study met its primary endpoint. The company maintains that it will file a New Drug Application (NDA) in the U.S. by the end of next month. It will also continue all other ongoing activities.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM